AcelRx Pharmaceuticals Appoints Vice-President Of Commercial Strategy
This article was originally published in Scrip
AcelRx Pharmaceuticals, a company focused on acute pain, has appointed Gina Ford vice-president of commercial strategy. She has worked with the company since 2013 as consultant and was involved in the development of a commercial strategy for Zalviso (sufentanil), which is now approved in Europe. Prior to joining AcelRx, Ford ran her own consulting firm. She was also president of Accesia (a wholly owned subsidiary of Patient Services, Inc.) and has also held various leadership positions at Ipsen.